INCY
NasdaqINCYTE CORPORATION
Industrials · Services-Commercial Physical & Biological Research
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$3.0B
2021
$3.4B
2022
$3.7B
2023
$4.2B
2024
$5.1B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$5.1B
Net Income$1.3B
Gross Profit—
Oper Income$1.5B
EPS (dil)$6.41
Rev/sh$25.73
FCF/sh—
Book/sh$25.87
Gross M—
Oper M29.5%
Profit M25.0%
FCF M—
ROE24.9%
ROA18.5%
ROIC5.6%
R&D/Rev39.9%
Rev Y/Y21.2%
Rev 3Y CAGR14.8%
EPS Y/Y4173.3%
EPS 3Y CAGR61.6%
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y-4.7%
Current Ratio3.32
Quick Ratio3.25
Debt/Eq3.68
Int Coverage623.9×
Net Debt$15.9B
Total Debt$19.0B
Cash & Eq$3.1B
Total Assets$7.0B
Oper CF$1.4B
Capex—
Free CF—
Buybacks$0
Equity$5.2B
Liabilities$1.8B
Shs Outstand0.20B
SectorIndustrials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.0B | $3.4B | $3.7B | $4.2B | $5.1B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $585.8M | $579.4M | $620.5M | $61.4M | $1.5B |
| Net Income | $948.6M | $340.7M | $597.6M | $32.6M | $1.3B |
| Diluted EPS | $4.27 | $1.52 | $2.65 | $0.15 | $6.41 |
| Operating Cash Flow | $749.5M | $969.9M | $496.5M | $335.3M | $1.4B |
| Free Cash Flow | — | — | — | — | — |
COMMUNITY · $INCY0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.